Chemotherapy-Induced Peripheral Neuropathy Incidence and Risk Factors from 23 Studies

23 studies involving 15,090 cancer patients were included in a systematic review and meta-analysis. The dataset reports a 56% incidence of chemotherapy-induced peripheral neuropathy and identifies 16 influencing factors with odds ratios. The analysis was conducted by He Yan and published on figshare in March 2026.

Use Cases

• Predicting CIPN risk in cancer patients based on identified factors like age, BMI, and diabetes.
• Training models to stratify patients by neuropathy risk using chemotherapy regimen details.
• Analyzing the strength of association for factors like vitamin D deficiency or cumulative drug dose.
• Benchmarking clinical trial outcomes against the reported 56% incidence rate.

Strengths

• Results are derived from a meta-analysis of 23 studies with a combined sample of 15,090 cases.
• Provides specific odds ratios for 16 distinct influencing factors, such as BMI ≥30 kg/m² (OR=1.67).
• Has a clear, open license (CC-BY-4.0) and is associated with a PROSPERO systematic review registration.

Limitations

• Row count and column-level documentation are unknown; data structure must be inferred from the DOCX file.
• The dataset is very small (23.6 KB), suggesting it contains summary results rather than raw patient-level data.

Provenance

Source

He Yan via figshare.

Collection Method

Systematic review and meta-analysis of studies from PubMed, Embase, Cochrane Library, and Web of Science up to June 10, 2025.

Time Range

Studies included up to June 10, 2025.

Freshness

Last updated 2026-03-17 13:04:52.

Geography

null